TrialTargeted oncology2026

FGF/FGFR Alteration Type as a Candidate Enrichment Biomarker for Gunagratinib in Recurrent or Metastatic Head and Neck Cancer: An Exploratory Analysis of Two Early-Phase Trials.

Liqiong Xue et al.PubMed ↗Publisher ↗

No numbers read from the abstract.